August 5, 2025

Real-world infectious complications of CD3/CD20 bispecific antibodies in relapsed/refractory non-Hodgkin lymphoma

Puntos clave

In this observation, 50% of patients treated with bispecific antibodies had any-grade infections.
The average infection rates per patient at 12 months were 1.3, with 23% experiencing grade ≥3 infections.
Severe treatment-related conditions like neutropenia and lymphopenia were seen in many patients, raising concerns.
Infection risk correlated with lower overall survival (HR 3.4, p = 0.0066), stressing the need for monitoring post-treatment.

Resumen

Infections occur in up to 44% of trial participants treated with CD3/CD20 bispecific antibodies (BsAb), but real-world data are limited. In this study of 48 real-world R/R-NHL patients receiving commercial BsAbs, 50% and 23% experienced any-grade and grade ≥3 infections, respectively. The cumulative number of infections per patient at 12 months was 1.3 (95% CI: 0.81-2.1). Severe infections were mostly bacterial. Only 1 grade 5 event occurred, and no COVID-19-related deaths were observed. Severe neutropenia, lymphopenia, and hypogammaglobulinemia occurred in 39.6, 83.3, and 64.1% of patients, respectively. In exploratory univariate analyses, recent infection, aggressive histology, number of prior lines of therapy, CAR T exposure, and severe treatment-emergent lymphopenia and hypogammaglobulinemia were linked to increased infection risk. Moreover, infection was associated with decreased overall survival (HR 3.4, p = 0.0066) in the Cox proportional hazards model. These real-world findings reinforce the need for monitoring of infectious complications following BsAb therapy.

Me gusta

Guardar

Cite This Study

Xiao et al. (Tue,) studied this question.

synapsesocial.com/papers/689522189f4f1c896c429e1a https://doi.org/https://doi.org/10.1080/10428194.2025.2540442

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

Me gusta

Guardar